Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193).

× No keyword cloud information.

19 in total

1. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.

Authors: E Olah; Y Natsumeda; T Ikegami; Z Kote; M Horanyi; J Szelenyi; E Paulik; T Kremmer; S R Hollan; J Sugar
Journal: Proc Natl Acad Sci U S A Date: 1988-09 Impact factor: 11.205

2. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.

Authors: D Raghavan; J Bishop; D Sampson; J Grygiel; R Woods; A Coates; R Fox
Journal: Cancer Chemother Pharmacol Date: 1986 Impact factor: 3.333

3. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Authors: T D Colby; K Vanderveen; M D Strickler; G D Markham; B M Goldstein
Journal: Proc Natl Acad Sci U S A Date: 1999-03-30 Impact factor: 11.205

Review 4. Tiazofurin: a new antitumor agent.

Authors: P J O'Dwyer; D D Shoemaker; H N Jayaram; D G Johns; D A Cooney; S Marsoni; L Malspeis; J Plowman; J P Davignon; R D Davis
Journal: Invest New Drugs Date: 1984 Impact factor: 3.850

Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193).

1. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.

2. Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion.

3. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.

Review 4. Tiazofurin: a new antitumor agent.

5. Guanine ribonucleotide depletion in mammalian cells. A target of purine antimetabolites.

6. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.

Review 7. Mechanism targeted discovery of antitumor marine natural products.

8. Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

9. Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.

10. Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).